Canopy Growth’s Insider Sales Undercut a Rare String of Positive Quarterlies

Canopy Growth's CEO sold 135,231 shares amid a 10% revenue rise and MTL acquisition; net loss persists but balance sheet strengthens with $131.3M cash.

Canopy Growth’s chief executive has cashed out 135,231 shares of the cannabis company, a move that sits uncomfortably alongside the most encouraging quarterly report the group has delivered in years. The transaction on 22 June, followed by further insider disposals on 29 June, brought the total value of shares sold by senior management over the past three months to $217,137. The timing is awkward: the sales come just days after the company posted a 10% rise in fourth-quarter consolidated net revenue, to $71.2m, and weeks after the close of a transformational acquisition.

The figures behind that report show a business in the midst of a genuine operational shift. Canopy’s cannabis segment generated $54.5m in the quarter, a 20% jump year-on-year. Canadian medical cannabis revenue surged 27%, while international markets — where the company is now growing at triple-digit rates according to the primary article — advanced 68%. Yet the bottom line remains deep in the red: the full fiscal year 2026 ended with a net loss of $154.7m. The numbers explain why the stock trades at just €0.84, down almost 19% since January and 58% below the 52-week high of €2.00 set last December.

A stronger balance sheet, but still bleeding cash

The improvement on the liability side is unmistakable. Canopy closed the fiscal year with net cash of $131.3m, a dramatic swing from the net debt position a year earlier. Management points to this as a platform for strategic flexibility, and the market has taken modest note: the stock climbed 1.46% on the day of the insider-sale report and is up nearly 4% over the past week. But the 30-day chart tells a different story, with a decline of 8.55%, and the share price remains 16% below its 200-day moving average of €1.00. Technical analysts now eye the 50-day line at €0.91 as a first resistance test, while the 52-week trough of €0.75 acts as a floor that could come into play if the recovery stalls.

The March 2026 acquisition of MTL Cannabis has already delivered on its promised cost synergies of $6m annually, according to the company, and vaulted Canopy to the top of Canada’s medical cannabis rankings by revenue. In Europe, the group re-launched its Tweed brand in Germany in May, featuring new MTL strains, and during the first fiscal quarter of 2027 it introduced infused pre-rolls and all-in-one vaporizers — high-growth categories in the Canadian recreational market. Management has also confirmed plans to enter the UK market in the current fiscal year.

The bull case rests on execution, not promises

Investors pinning hopes on a sustained turnaround point to the combination of a dominant domestic medical position and triple-digit international expansion. If Canopy can push its adjusted EBITDA positive — the target for fiscal 2027, reaffirmed during the 1 July earnings call — the stock could mount a challenge to the 50-day average and begin forming a genuine base. The integration of MTL and the German push are the two critical deliverables. The primary article notes that the market is waiting for the first full quarter of MTL’s contribution, as well as measurable results from the German operations, and expects clear answers by the third quarter of calendar 2026.

Insider selling raises the bearish counter-argument

The CEO’s share disposal, however, injects a note of caution that the quarterly numbers alone cannot dispel. Whether the move represents routine portfolio rebalancing or a deeper unease about the near-term trajectory is impossible to determine from the outside, but it adds to a list of structural headwinds. Canopy is still posting net losses, its stock has high volatility above 33%, and the integration costs of MTL remain an untested variable. The technical picture is weak: the share price sits below both the 50-day and 200-day moving averages, and the year-to-date loss of 18.64% reflects persistent selling pressure.

For now, Canopy Growth offers two competing narratives. The optimist sees a company that has repaired its balance sheet, found a profitable niche in medical cannabis, and is expanding into high-margin product categories in Europe and the UK. The pessimist notes that insiders are reducing their exposure even as management talks up the plan, that the cash-flow deficit has yet to turn, and that the stock has given back all of its post-acquisition gains. The third quarter of 2026 — whether it brings a clean beat on revenue and a path to EBITDA positivity, or another round of red ink — will decide which story prevails.